Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
News|Articles|March 7, 2015
Thyroid Hormone Receptor and Runx2 Expression in Thyroid Cancer Cells
Author(s)Frances Carr, PhD
Frances Carr, PhD, professor, Department of Pharmacology, The University of Vermont, discusses the relationship between the thyroid hormone receptor and Runx2 expression in thyroid cancer cells.
Advertisement
References
Frances Carr, PhD, professor, Department of Pharmacology, The University of Vermont, discusses the relationship between the thyroid hormone receptor and Runx2 expression in thyroid cancer cells.
- The thyroid hormone receptor is a possible tumor suppressor.
- Studies have shown that Runx2 may be a tumor promoter in papillary thyroid cancer.
- An inverse relationship was seen between thyroid hormone receptor expression and Runx2.
- This relationship is being explored and could have therapeutic implications in the future.
Advertisement
Related to this article
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5